

CooperVision®

209 High Point Drive
Suite 100
Victor, NY 14564


T 585 756 9500
cooprision.com

November 2024

IMPORTANT BIOMEDICS® 55 PREMIER AND BIOMEDICS® TORIC DISCONTINUATION ANNOUNCEMENT

Dear Eye Care Practitioner,

At CooperVision®, we continually push to improve every lens we make and are committed to bringing the latest technology to you and your patients. In order to simplify our product line and allow you to focus on fitting your patients in more innovative products to better address their needs, CooperVision® is discontinuing Biomedics® 55 Premier and Biomedics® toric trials on May 1, 2025, and revenue packs on May 1, 2026.



Consider providing your patients a healthier lens wearing experience*

As Eye Care Professionals, your patients look to you to recommend the best option for their eyes¹. Therefore, CooperVision® recommends upgrading your patients to **clariti® 1 day** or **Biofinity®** monthly replacement lenses. Take advantage of newer technologies and upgrade your patients from Biomedics® 55 Premier and Biomedics® toric to silicone hydrogel 1-day or monthly lenses. In doing so, you will benefit from:

- Maximizing patient satisfaction^{†‡}
- Management of contact lens drop out
- Saving your patients money with high-value patient rebates

If you'd prefer to keep your patients within the 2-week modality, **Avaira Vitality®** is another option.

Please use the chart below to provide upgrade or refit options to your patients.

PRODUCT	MATERIAL	WATER CONTENT	BASE CURVE (mm)	DIAMETER (mm)	SPHERE POWER	Dk/t (AT -3.00D)	
2-Week Discontinuation	Biomedics® 55 Premier	ocufilcon D	55%	8.6	-0.25D to -10.00D (0.50D steps after -6.00D)	26	
				8.9	+0.25D to +8.00D (0.50D steps after +5.00D)		
1-day	clariti® 1 day	somofilcon A	56%	8.8	14.2	+8.00D to -10.00D (0.50D steps after +/-6.00D), no plano	86
Monthly	Biofinity Energys®	comfilcon A	48%	8.6	14.0	+8.00D to -12.00D (0.50D steps after +/-6.00D), no plano	160
	Biofinity® & Biofinity® XR	comfilcon A	48%	8.6	14.0	+15.00D to -20.00D (0.50D steps after +/-6.00D), no plano	160
2-Week	Avaira Vitality®	fanfilcon A	55%	8.4	14.2	+8.00D to -12.00D (0.50D steps after +/-6.00D), no plano	110

NEW
WEARER
patient
rebate
available

*With high oxygen delivery for daily wear, SiHy materials minimize or eliminate hypoxia-related complications. †Observational satisfaction survey involving 1718 patients (new lens wearers n=1091, refitted lens wearers n=627) who were fitted with clariti® 1 day: 97% Very satisfied, and rather satisfied-ophthalmologist overall satisfaction. ‡ On average, 85% strongly/somewhat agree.


	PRODUCT	MATERIAL	WATER CONTENT	BASE CURVE (mm)	DIAMETER (mm)	SPHERE POWER	CYLINDER POWER	AXIS	Dk/t (AT -3.00D)
2-Week Discontinuation	Biomedics® toric	ocufilcon D	55%	8.7	14.2	+6.00D to -10.00D (0.50D steps after +5.00D and -6.00D)	-0.75D, -1.25D, -1.75D, -2.25D	Full circle in 10° steps	18
1-day	clariti® 1 day toric	somofilcon A	56%	8.6	14.3	Plano to -6.00D (0.25D steps)	-0.75D, -1.25D, -1.75D	Full circle in 10° steps	57
							-2.25D	10°, 20°, 70°, 80°, 90°, 100°, 160°, 170°, 180°	
						-6.50D to -9.00D (0.50D steps)	-0.75D, -1.25D, -1.75D	10°, 20°, 60°, 70°, 80°, 90°, 100°, 110°, 120°, 160°, 170°, 180°	
							-2.25D	10°, 20°, 90°, 160°, 170°, 180°	
						+0.25D to +4.00D (0.25D steps)	-0.75D, -1.25D, -1.75D	10°, 20°, 70°, 80°, 90°, 100°, 160°, 170°, 180°	
Monthly	Biofinity® toric	comfilcon A	48%	8.7	14.5	+8.00D to -10.00D (0.50D steps after +/-6.00D)	-0.75D, -1.25D, -1.75D, -2.25D	10° to 180° in 10° steps	116
2-Week	Avaira Vitality® toric	fanfilcon A	55%	8.5	14.5	+8.00D to -10.00D (0.50D steps after +/-6.00D)	-0.75D, -1.25D, -1.75D, -2.25D	10° to 180° in 10° steps	90

NEW
WEARER
Patient
rebate
available

If you have questions about these products, rebates or plans to discontinue Biomedics® 55 Premier and Biomedics® toric, please contact your CooperVision® Sales Representative or call 800 341 2020. You can also learn more about our products by visiting cooprision.com. Learn more about rebates at cooprision.com/rebates.

Thank you for your business and continued support.

Sincerely,
Sales and Marketing
CooperVision, Inc.



References:

1. Data on file. December 2015 contact lens wearer survey; n=1193.

2. CVI data on file 2021. Decision Analyst online survey of 376 Biofinity prescribing ECPs in USA, Japan, Germany, France and Spain.